Search research articles
Contact Us
Filters
Showing results (221-230 of 225) with videos related to
Page
of 23
Sort By:
You have reached the last page of results.
This site can display upto 225 results.
Proceedings of the National Academy of Sciences of the United States of America
|
March 16, 2007
A haplotype of the human CXCR1 gene protective against rapid disease progression in HIV-1+ patients
A Vasilescu, Y Terashima, M Enomoto, et al.
Applied Optics
|
March 25, 2008
X-Ray Telescope Onboard Astro-E. II. Ground-Based X-Ray Characterization
R Shibata, M Ishida, H Kunieda, et al.
Applied Optics
|
March 22, 2008
X-ray telescope onboard Astro-E: optical design and fabrication of thin foil mirrors
H Kunieda, M Ishida, T Endo, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|
February 1, 1996
[Phase II study of paclitaxel (BMS-181339) in patients with ovarian cancer by 3-hour intravenous infusion]
K Noda, M Ikeda, R Kudo, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|
December 5, 1998
[Early phase II trial of oral etoposide administered for 21 consecutive days in patients with cervical or ovarian cancer. ETP 21 Study Group--Cervical-Ovarian Cancer Group]
K Noda, K Tanaka, M Ozaki, et al.
Page
of 23
Search research articles
Search
Showing results (221-230 of 225) with videos related to
Sort By:
Page
of 23
You have reached the last page of results.
This site can display upto 225 results.
Proceedings of the National Academy of Sciences of the United States of America
|
March 16, 2007
A haplotype of the human CXCR1 gene protective against rapid disease progression in HIV-1+ patients
A Vasilescu, Y Terashima, M Enomoto, et al.
Applied Optics
|
March 25, 2008
X-Ray Telescope Onboard Astro-E. II. Ground-Based X-Ray Characterization
R Shibata, M Ishida, H Kunieda, et al.
Applied Optics
|
March 22, 2008
X-ray telescope onboard Astro-E: optical design and fabrication of thin foil mirrors
H Kunieda, M Ishida, T Endo, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|
February 1, 1996
[Phase II study of paclitaxel (BMS-181339) in patients with ovarian cancer by 3-hour intravenous infusion]
K Noda, M Ikeda, R Kudo, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|
December 5, 1998
[Early phase II trial of oral etoposide administered for 21 consecutive days in patients with cervical or ovarian cancer. ETP 21 Study Group--Cervical-Ovarian Cancer Group]
K Noda, K Tanaka, M Ozaki, et al.
Page
of 23